Montoro Ronsano, José Bruno
Montoro JB
VIAF ID: 86707222 (Personal)
Permalink: http://viaf.org/viaf/86707222
Preferred Forms
- 100 0 _ ‡a Montoro JB
-
- 100 1 _ ‡a Montoro Ronsano, José Bruno
- 100 1 0 ‡a Montoro Ronsano, José Bruno
4xx's: Alternate Name Forms (15)
Works
Title | Sources |
---|---|
[The 2013 Seville Consensus Document on alternatives to allogenic blood transfusion. An update on the Seville Document]. | |
Aspectos farmacéuticos de la biotecnología | |
Avaluació de l’efectivitat i la seguretat dels anticoagulants orals d'acció directa en pacients amb fibril·lació auricular sotmesos a intervencionisme coronari percutani amb implantació d'stent | |
Avaluació de l'efectivitat i la seguretat del cinacalcet en pacients amb malaltia renal crònica i hiperparatiroïdisme secundari sense tractament renal substitutiu | |
Avaluació prospectiva de la taxa de publicació dels resultats dels assaigs clínics i anàlisi del biaix de publicació | |
Benefits of FK506 (tacrolimus) for residual, cyclosporin- and prednisone-resistant myasthenia gravis: one-year follow-up of an open-label study. | |
Capacitat predictiva de l'estimació de la funció renal sobre la cinètica d'eliminació de ganciclovir | |
Comment: compatibility of amphotericin B with lipid emulsions | |
Comment: Use of recalibrated serum creatinine concentrations for adjustment of drug dosages: determination of values compatible with conventional dosing recommendations | |
Comparative study of four different pharmacokinetic computer programs: case study of a factor VIII preparation. | |
Comparison of the Cockcroft-Gault, MDRD and CKD-EPI equations for estimating ganciclovir clearance | |
El consumo de cannabis y derivados en la provincia de Barcelona : analítica de las muestras aprehendidas | |
Continuous infusion of factor VIII concentrate to a patient with severe von Willebrand disease | |
Contribución al estudio de los concentrados de factor VIII de la coagulación | |
[Current framework of biotechnology products according to the available pharmacoeconomic studies] | |
Dèficit greu d'alfa-1-antitripsina : individualització del tractament substitutiu | |
[Drug-drug interactions: new aspects] | |
Efectividad del concentrado de fibrinógeno en pacientes traumáticos con hemorragia crítica | |
Effect of atorvastatin on lipoprotein (a) and interleukin-10: A randomized placebo-controlled trial | |
Effects of competition and its outcome on serum testosterone, cortisol and prolactin | |
Epidemiology of injuries in elite taekwondo athletes: two Olympic periods cross-sectional retrospective study. | |
Evaluation of the efficiency under current use of human fibrinogen concentrate in trauma patients with life-threatening hemorrhagic disorders. | |
Farmacocinética de la alfa-1-antitripsina utilizada en el tratamiento sustitutivo del enfisema congénito grave | |
Farmacoterapia del trasplante de órganos | |
How long should we continue to use the Cockcroft-Gault formula for dose-adjustment of drugs in renal failure? | |
Immunoglobulins for intravenous use (IVIg) : indications and technical characteristics | |
The impact of single nucleotide polymorphisms on patterns of non-contact musculoskeletal soft tissue injuries in a football player population according to ethnicity. | |
Inability of recombinant human thyrotropin to predict the evolution from subclinical hypothyroidism to overt disease. A pilot study | |
Influencia del tipo de lípidos de la nutrición parenteral sobre la retinopatía de la prematuridad | |
Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. | |
Inmunoglobulinas de uso intravenoso (IglV) | |
Inmunoglobulinas endovenosas : indicaciones y características técnicas | |
Interacciones fármacos-alimentos | |
Intravenous immunoglobulin preparations and autoimmune disorders: mechanisms of action. | |
Long-term effectiveness of cinacalcet in non-dialysis patients with chronic kidney disease and secondary hyperparathyroidism | |
Modulating effects of intravenous immunoglobulins on serum cytokine levels in patients with primary hypogammaglobulinemia | |
Physiopathology and treatment of critical bleeding: a literature review. | |
Positive outcomes influence the rate and time to publication, but not the impact factor of publications of clinical trial results | |
Posttransplant monomorphic Burkitt's lymphoma: clinical characteristics and outcome of a multicenter series | |
Recombinant factor VIIa in continuous infusion during central line insertion in a child with factor VIII high-titre inhibitor. | |
Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia | |
Role of a research ethics committee in follow-up and publication of results | |
[The Royal Decree on clinical trials reaches the age of 2] | |
Seroprevalence of parvovirus B19, cytomegalovirus, hepatitis A virus and hepatitis E virus antibodies in haemophiliacs treated exclusively with clotting-factor concentrates considered safe against human immunodeficiency and hepatitis C viruses. | |
Stability of somatostatin in total parenteral nutrition | |
Topical Administration of Bosentan Prevents Retinal Neurodegeneration in Experimental Diabetes | |
Transient factor VIII inhibitor and treatment with monoclonal-antibody-purified factor VIII. | |
Use and Outcomes of Triple Antithrombotic Therapy with Non-Vitamin K Antagonists in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention |